Striving for a cancer-free future

Investigating the genetic changes leading to acute myeloid leukaemia

Lead researcher

Marco Herold, Tony Papenfuss

Marco Herold, Tony Papenfuss

Institution
The Walter and Eliza Hall Institute

Tumour type:
Leukaemia

Years funded
2021-2023

Project description

Our project seeks to clarify the role of the mutated DNMT3a enzyme in the initiation and continuous growth of acute myeloid leukaemia (AML). Little work to date has gone into studying the gene expression changes caused by mutant DNMT3a in AML. Identifying the most critical altered gene products in DNMT3a mutant AML will open new possibilities for developing drugs to improve treatment for this devastating disease.

What is the need? 

Patients with AML face a lethal outcome without effective treatment. Initial responses to standard chemotherapy are good, but relapses are unfortunately common. Because of this, more targeted and more effective therapies for AML are urgently needed.

My goal is to identify new targets for cancer therapy which ultimately improve the life quality and chances of a cure for cancer patients.

What are you trying to achieve?

The project aims to identify novel cancer-causing pathways in acute myeloid leukemia with mutations in DNMT3a. Ultimately these pathways will represent novel targets for new and better anti-cancer treatments.

How important is this funding?

AML is a devastating disease. Better and more enduring treatment options are desperately required. Funding through Cancer Council allows us to pursue new avenues for improving our understanding of AML and developing new anti-cancer therapies.

Project timeline

Timeline 2021 2022 2023
Build library targeting known and new co-drivers of DNMT3a mutant AMLs; start generating mutant cancers      
Identify co-drivers of DNMT3a mutant AMLs; start genetic engineering and drug treatment of human AML samples      
Genetically validate newly identified targets and trial treatments      

Award / Duration

3 years